Ectonucleoside triphosphate diphosphohydrolase 6 expression in testis and testicular cancer and its implication in cisplatin resistance.

Yasuhiro Tada, Akira Yokomizo, Masaki Shiota, Yoohyun Song, Eiji Kashiwagi, Kentaro Kuroiwa, Yoshinao Oda, Seiji Naito

Oncology reports 2011 Jul

filter terms:

The development of resistance to cisplatin during treatment of testicular cancer constitutes a major obstacle to the cure of testicular cancer. To resolve its mechanism will provide useful information for making clinical decisions. We found 4 and 15 gene expressions were, respectively, up-regulated and down-regulated in cisplatin-resistant testicular cancer NEC-8/DDP cells compared with their parental NEC-8 cells (about 2.5-fold) using cDNA microarray analysis. After screening, we selected the ENTPD6 among these 19 genes. ENTPD6 was less expressed in cancerous region compared with that in non-cancerous lesion. In addition, ENTPD6 expression in seminoma was higher than that in other testicular tumors. ENTPD6 expression was involved in cellular sensitivity to cisplatin through an interaction with E-cadherin. ENTPD6 is a promising molecular biomarker of cisplatin resistance in testicular cancer, and also a novel therapeutical target modulating cisplatin resistance in testicular cancer.

Citation

Yasuhiro Tada, Akira Yokomizo, Masaki Shiota, Yoohyun Song, Eiji Kashiwagi, Kentaro Kuroiwa, Yoshinao Oda, Seiji Naito. Ectonucleoside triphosphate diphosphohydrolase 6 expression in testis and testicular cancer and its implication in cisplatin resistance. Oncology reports. 2011 Jul;26(1):161-7